The study evaluates the experience with using a Molecular Tumor Board (MTB) in the implementation of personalized oncology treatment for patients with advanced solid tumors in whom standard therapeutic options had been exhausted. Between February 2021 and April 2025, 553 patients were enrolled in the MTB, with a median age of 61 years; women predominated (62%). The most common diagnoses included colorectal cancer, cholangiocarcinoma, and pancreatic cancer.
Based on molecular profiling, targeted therapy was recommended for 59% of patients. In 17% of these cases, the therapy was actually initiated, with some patients demonstrating confirmed clinical benefit. The study highlights the diagnostic potential of the MTB, while also pointing to the persistent barriers to access to targeted therapy in clinical practice.
More information about the publication is available at the following link: Real‐World Data From a Molecular Tumor Board‐Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients? - Eid - 2025 - Cancer Medicine - Wiley Online Library